• Vancomycin Hydrochloride in Resistance Workflows

  2026-09-29

  Build more interpretable Gram-positive susceptibility, resistance, and infection-model workflows with a mechanistically defined comparator. This guide connects practical stock preparation and assay controls with emerging antimicrobial-peptide research, while separating evidence-backed parameters from pilot conditions that require local optimization.

• β-NMN Workflows for Metabolic Research

  2026-09-29

  Build reproducible NAD+ manipulation experiments with beta-Nicotinamide mononucleotide (β-NMN), from islet secretion assays to diabetic cardiac-remodeling models. This practical guide separates reported findings from suggested starting conditions and emphasizes formulation, controls, and mechanism-aware troubleshooting.

• MCL-1 Inhibition: From Mechanism to Translation

  2026-09-28

  MCL-1 inhibitor A-1210477 offers a selective way to test how cancer cells evade mitochondrial apoptosis. This thought-leadership guide connects MCL-1 biology, BAX/BAK-informed validation, combination strategy, experimental handling, and translational decision-making while defining the compound’s limits as an in vitro research tool.

• Bacitracin (B1670): Practical Research Guide

  2026-09-28

  Bacitracin (B1670) is a peptide antibiotic for controlled laboratory studies of bacterial growth and cell-wall or peptidoglycan synthesis disruption. Use it to investigate antibacterial effects under locally validated assay conditions; it is not intended for diagnostic, clinical, or medical use.

• Bufalin in HCC: Assay Workflow and Mechanistic Insight

  2026-09-27

  Use Bufalin to test how CENPA-associated glycolysis and PI3K/AKT signaling relate to hepatocellular carcinoma cell migration—not simply to measure viability. This guide turns recent HCC findings into a staged workflow with practical controls, optimization steps, and clear boundaries between reported evidence and suggested pilot conditions.

• Griseofulvin: A Workflow for Microtubule Assays

  2026-09-26

  Use Griseofulvin to investigate how microtubule disruption affects fungal growth, then adapt a carefully controlled mechanistic workflow to ask whether a cellular response is consistent with aneugenicity. This guide separates established reference-assay findings from practical starting conditions that researchers should optimize for their own model.

• Verapamil and the Timing of Urothelial Inflammation

  2026-09-25

  Verapamil ((±)-Verapamil) helps probe how hypoxia duration relates to urothelial inflammatory signaling. This article focuses on experimental interpretation: separating an early hypoxic response from later caspase-1 activation and recognizing what a pharmacological intervention can—and cannot—establish.

• Neuromedin S (rat): Assay and Handling Guide

  2026-09-25

  Neuromedin S (rat) provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein responses. Use it in research assays with suitable vehicle and receptor controls; it is not intended for diagnosis, treatment, or clinical use.

• Deferasirox in Nutrient-Stress and Lysosome Research

  2026-09-24

  Deferasirox is an oral iron chelator that can help researchers probe how iron availability intersects with nutrient stress and cell death. This article connects its iron-binding properties to recent TCF25–lysosome findings while clarifying what the experiments do—and do not—establish.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-09-24

  A 2024 study reports that reduced PPP2R2A expression increases replication stress and makes high-grade serous ovarian cancer (HGSOC) cells more vulnerable to CHK1 inhibition. The findings support PPP2R2A/PP2A B55α as a candidate response biomarker, including in PARP inhibitor-resistant models, but remain preclinical and require clinical validation.

• Vancomycin Hydrochloride: From Mechanism to Models

  2026-09-23

  A translational perspective on using vancomycin hydrochloride as a mechanistic benchmark—from D-Ala-D-Ala target engagement and susceptibility assays to infection-model design and comparison with antimicrobial peptides.

• Bobcat339: TET Inhibitor Workflow for Epigenetics

  2026-09-23

  Bobcat339 provides a practical pharmacological route to test whether TET1/2-dependent DNA demethylation contributes to gene regulation, stem-cell behavior, and osteogenic failure. This guide combines dose-finding, methylation and chromatin readouts, multi-omics integration, and troubleshooting for disease-relevant epigenetics workflows.

• Auranofin at the Redox–Mechanobiology Interface

  2026-09-22

  Auranofin is more than a thioredoxin reductase inhibitor: it can serve as a translational probe for testing how redox resilience shapes mechanically induced autophagy, apoptosis, and radiosensitivity. This article connects the compound’s established redox biology with cytoskeleton-dependent mechanotransduction, while distinguishing published evidence from forward-looking experimental hypotheses.

• Sorafenib Workflow for Liver Cancer Research

  2026-09-22

  Learn how to use Sorafenib, also known as BAY-43-9006, as a reproducible benchmark for RAF/MEK/ERK signaling, VEGF-dependent angiogenesis, and tumor proliferation inhibition. The workflow also shows how to compare kinase blockade with the cholesterol-driven mitophagy mechanism reported in a recent liver cancer study.

• PPP2R2A Loss Sensitizes Ovarian Cancer to CHK1 Inhibition

  2026-09-21

  The 2024 Theranostics study identifies low PPP2R2A expression as a potential biomarker of CHK1-inhibitor sensitivity in high-grade serous ovarian cancer (HGSOC). Its experiments connect PP2A B55α deficiency with increased replication initiation, c-Myc-associated replication stress, and CHK1 dependence, including in models resistant to PARP inhibitors.

8123 records 1/542 page Next 12345 下5页 Last page